The importance of the glycosylation of antimicrobial peptides: natural and synthetic approaches

Drug Discovery Today

Volumn 22, Issue 6, 2017, Pages 919-926

  Bednarska, Natalia G ^a   Wren, Brendan W ^a   Willcocks, Sam J ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

POLYPEPTIDE ANTIBIOTIC AGENT; ANTIMICROBIAL CATIONIC PEPTIDE;

ADAPTIVE IMMUNITY; ANTIMICROBIAL ACTIVITY; DRUG DESIGN; DRUG POTENCY; DRUG SYNTHESIS; GLYCOSYLATION; IMMUNOMODULATION; NONHUMAN; REVIEW; ANIMAL; HUMAN; METABOLISM; PROTEIN PROCESSING;

ANIMALS; ANTIMICROBIAL CATIONIC PEPTIDES; GLYCOSYLATION; HUMANS; PROTEIN PROCESSING, POST-TRANSLATIONAL;

EID: 85013053172     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2017.02.001     Document Type: Review

References (92)

1. Cuccui, J., et al. Exploitation of bacterial N-linked glycosylation to develop a novel recombinant glycoconjugate vaccine against Francisella tularensis. Open Biol., 3, 2013, 130002.
2. Cuccui, J., Wren, B., Hijacking bacterial glycosylation for the production of glycoconjugates, from vaccines to humanised glycoproteins. J. Pharm. Pharmacol 67 (2015), 338–350.
3. Pinho, S.S., Reis, C.A., Glycosylation in cancer: mechanisms and clinical implications. Nat. Rev. Cancer 15 (2015), 540–555.
4. Hansen, J.E., et al. Prediction of O-glycosylation of mammalian proteins: specificity patterns of UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase. Biochem. J. 308 (1995), 801–813.
5. Peter-Katalinic, J., Methods in enzymology: O-glycosylation of proteins. Methods Enzymol. 405 (2005), 139–171.
6. Nishikawa, T., et al. C-Glycosylation BT. Fraser-Reid, B.O., et al. (eds.) Glycoscience: Chemistry and Chemical Biology, 2008, Springer, 755–811.
7. Hartmann, S., Hofsteenge, J., Properdin, the positive regulator of complement, is highly C-mannosylated. J. Biol. Chem. 275 (2000), 28569–28574.
8. Doucey, M.-A., et al. Protein C-mannosylation is enzyme-catalysed and uses dolichyl-phosphate-mannose as a precursor. Mol. Biol. Cell 9 (1998), 291–300.
9. Oman, T.J., et al. Sublancin is not a lantibiotic but an S-linked glycopeptide. Nat. Chem. Biol. 7 (2011), 78–80.
10. Stepper, J., et al. Cysteine S-glycosylation, a new post-translational modification found in glycopeptide bacteriocins. FEBS Lett. 585 (2011), 645–650.
11. Wang, G., Post-translational modifications of natural antimicrobial peptides and strategies for peptide engineering. Curr. Biotechnol. 1 (2012), 72–79.
12. Andreu, D., Rivas, L., Animal antimicrobial peptides: an overview. Biopolymers 47 (1998), 415–433.
13. Opdenakker, G., et al. Cells regulate the activities of cytokines by glycosylation. FASEB J. 9 (1995), 453–457.
14. Moradi, S.V., et al. Glycosylation, an effective synthetic strategy to improve the bioavailability of therapeutic peptides. Chem. Sci. 7 (2016), 2492–2500.
15. Woschnagg, C., et al. Eosinophil cationic protein (ECP) is processed during secretion. J. Immunol. 183 (2009), 3949–3954.
16. Rubin, J., Venge, P., Asparagine-linked glycans determine the cytotoxic capacity of eosinophil cationic protein (ECP). Mol. Immunol. 55 (2013), 372–380.
17. Salazar, V.A., et al. Protein post-translational modification in host defense: the antimicrobial mechanism of action of human eosinophil cationic protein native forms. FEBS J. 281 (2014), 5432–5446.
18. Lele, D.S., et al. Understanding the importance of glycosylated threonine and stereospecific action of Drosocin, a Proline rich antimicrobial peptide. Eur. J. Med. Chem. 92 (2015), 637–647.
19. Talat, S., et al. Glycosylated analogs of formaecin I and drosocin exhibit differential pattern of antibacterial activity. Glycoconj. J. 28 (2011), 537–555.
20. Maky, M.A., et al. Enterocin F4-9, a novel O-linked glycosylated bacteriocin. Appl. Env. Microbiol. 81 (2015), 4819–4826.
21. Hong, P.K., et al. Glycation and transglutaminase mediated glycosylation of fish gelatin peptides with glucosamine enhance bioactivity. Food Chem. 142 (2014), 2852–2893.
22. Mandal, S.M., A novel hydroxyproline rich glycopeptide from pericarp of Datura stramonium: proficiently eradicate the biofilm of antifungals resistant Candida albicans. Biopo lymers 98 (2012), 332–337.
23. Trulson, A., et al. The functional heterogeneity of eosinophil cationic protein is determined by a gene polymorphism and post-translational modifications. Clin. Exp. Allergy 37 (2007), 208–218.
24. Huang, C.Y., et al. Site-specific N-glycosylation of caprine lysostaphin restricts its bacteriolytic activity toward Staphylococcus aureus. Anim. Biotechnol. 24 (2013), 129–147.
25. Harrison, R.L., Jarvis, D.L., Protein N‐glycosylation in the baculovirus–insect cell expression system and engineering of insect cells to produce ‘mammalianized’ recombinant glycoproteins. Insect Viruses Biotechnol. Appl. 68 (2006), 159–191.
26. Brudzynski, K., Sjaarda, C., Honey glycoproteins containing antimicrobial peptides, Jelleins of the Major Royal Jelly Protein 1, are responsible for the cell wall lytic and bactericidal activities of honey. PLoS ONE, 10, 2015, e0120238.
27. Wormald, M.R., et al. The conformational effects of N-glycosylation on the tailpiece from serum IgM. Eur. J. Biochem. 198 (1991), 131–139.
28. Lommerse, J.P., et al. Conformations and internal mobility of a glycopeptide derived from bromelain using molecular dynamics simulations and NOESY analysis. J. Biomol. NMR 6 (1995), 79–94.
29. Bosques, C.J., Imperiali, B., The interplay of glycosylation and disulfide formation influences fibrillization in a prion protein fragment. Proc. Natl. Acad. Sci. U. S. A. 100 (2003), 7593–7598.
30. O'Connor, S.E., Imperiali, B., A molecular basis for glycosylation-induced conformational switching. Chem. Biol. 5 (1998), 427–437.
31. Wormald, M.R., Dwek, R.A., Glycoproteins: glycan presentation and protein-fold stability. Structure 7 (2016), R155–60.
32. Shental-Bechor, D., Levy, Y., Effect of glycosylation on protein folding: a close look at thermodynamic stabilization. Proc. Natl. Acad. Sci. U. S. A. 105 (2008), 8256–8261.
33. Shental-Bechor, D., Levy, Y., Folding of glycoproteins: toward understanding the biophysics of the glycosylation code. Curr. Opin. Struct Biol. 19 (2009), 524–533.
34. Byrne, B., et al. Sialic acids: carbohydrate moieties that influence the biological and physical properties of biopharmaceutical proteins and living cells. Drug Discov. Today 12 (2007), 319–326.
35. Pozsgay, V., et al. Protein conjugates of synthetic saccharides elicit higher levels of serum IgG lipopolysaccharide antibodies in mice than do those of the O-specific polysaccharide from Shigella dysenteriae type 1. Proc. Natl. Acad. Sci. U. S. A. 96 (1999), 5194–5197.
36. Cheng, S., et al. Glycosylated enfuvirtide: a long-lasting glycopeptide with potent anti-HIV activity. J. Med. Chem. 58 (2015), 1372–1379.
37. Kozlowski, A., et al. Development of pegylated interferons for the treatment of chronic hepatitis C. BioDrugs 15 (2001), 419–429.
38. Pratt, M.R., Bertozzi, C.R., Synthetic glycopeptides and glycoproteins as tools for biology. Chem. Soc. Rev. 34 (2005), 58–68.
39. Lee, H.S., et al. Effects of N-glycosylation on protein conformation and dynamics: Protein Data Bank analysis and molecular dynamics simulation study. Sci. Rep., 5, 2015, 8926.
40. Aebi, M., N-linked protein glycosylation in the ER. Biochim. Biophys. Acta - Mol. Cell Res. 1833 (2013), 2430–2437.
41. Price, J.L., et al. Glycosylation of the enhanced aromatic sequon is similarly stabilizing in three distinct reverse turn contexts. Proc. Natl. Acad. Sci. U. S. A. 108 (2011), 14127–14132.
42. Hu, H., et al. Synthesis and antibacterial activities of N-glycosylated derivatives of tyrocidine A, a macrocyclic peptide antibiotic. J. Med. Chem. 52 (2009), 2052–2059.
43. Solá, R.J., Griebenow, K., Glycosylation of therapeutic proteins: an effective strategy to optimize efficacy. BioDrugs 24 (2010), 9–21.
44. Diebold, S.S., Activation of dendritic cells by toll-like receptors and C-type lectins. Handb. Ex. Pharmacol. 188 (2009), 3–30.
45. Brimble, M.A., et al. Synthesis of the antimicrobial S-linked glycopeptide, glycocin F. Chemistry 21 (2015), 3556–3561.
46. Wen, L.S., et al. Purification, characterization and mode of action of plantaricin K25 produced by Lactobacillus plantarum. Food Control 60 (2016), 430–439.
47. Sand, S.L., et al. Plantaricin A, a cationic peptide produced by Lactobacillus plantarum, permeabilizes eukaryotic cell membranes by a mechanism dependent on negative surface charge linked to glycosylated membrane proteins. Biochim. Biophys. Acta 1828 (2013), 249–259.
48. Erni, B., The mannose transporter complex: an open door for the macromolecular Invasion of bacteria. J. Bacteriol. 188 (2006), 7036–7038.
49. Donia, M.S., Fischbach, M.A., Small molecules from the human microbiota. Science, 349, 2015, 1254766.
50. Nolan, E.M., et al. Biosynthetic tailoring of microcin E492m: post-translational modification affords an antibacterial siderophore-peptide conjugate. J. Am. Chem. Soc 129 (2007), 14336–14347.
51. Strub, J.-M., et al. Antibacterial activity of glycosylated and phosphorylated chromogranin A-derived peptide 173-194 from bovine adrenal medullary chromaffin granules. J. Biol. Chem. 271 (1996), 28533–28540.
52. Harries, E., et al. Genes involved in protein glycosylation determine the activity and cell internalization of the antifungal peptide PAF26 in Saccharomyces cerevisiae. Fungal Genet. Biol. 58–59 (2013), 105–115.
53. Wolfert, M.A., Boons, G.-J., Adaptive immune activation: glycosylation does matter. Nat. Chem. Biol. 9 (2013), 776–784.
54. Weghuber, J., et al. Cationic amphipathic peptides accumulate sialylated proteins and lipids in the plasma membrane of eukaryotic host cells. Biochim. Biophys. Acta 1808 (2011), 2581–2590.
55. Gennaro, R., et al. Pro-rich antimicrobial peptides from animals: structure, biological functions and mechanism of action. Curr. Pharm. Des. 8 (2002), 763–778.
56. Liu, J., et al. Cathelicidin PR-39 peptide inhibits hypoxia/reperfusion-induced kidney cell apoptosis by suppression of the endoplasmic reticulum-stress pathway. Acta Biochim. Biophys. Sin. 48 (2016), 714–722.
57. Ohtake, T., et al. Proline-rich antimicrobial peptide, PR-39 gene transduction altered invasive activity and actin structure in human hepatocellular carcinoma cells. Br. J. Cancer 81 (1999), 393–403.
58. Werdelin, O., et al. Processing of glycans on glycoprotein and glycopeptide antigens in antigen-presenting cells. Proc. Natl. Acad. Sci. U. S. A. 99 (2002), 9611–9613.
59. Hancock, R.E., et al. The immunology of host defence peptides: beyond antimicrobial activity. Nat. Rev. Immunol. 16 (2016), 321–334.
60. Cobb, B.A., et al. Polysaccharide processing and presentation by the MHCII pathway. Cell 117 (2004), 677–687.
61. Speir, J.A., et al. Crystal structure of an MHC class I presented glycopeptide that generates carbohydrate-specific CTL. Immunity 10 (1999), 51–61.
62. Wu, Y.L., et al. gammadelta T cells and their potential for immunotherapy. Int. J. Biol. Sci. 10 (2014), 119–135.
63. Treanor, B., B-cell receptor: from resting state to activate. Immunology 136 (2012), 21–27.
64. Maverakis, E., et al. Glycans in the immune system and the altered glycan theory of autoimmunity: a critical review. J. Autoimmun. 57 (2015), 1–13.
65. Marth, J.D., Grewal, P.K., Mammalian glycosylation in immunity. Nat. Rev. Immunol. 8 (2008), 874–887.
66. Bork, K., et al. Increasing the sialylation of therapeutic glycoproteins: the potential of the sialic acid biosynthetic pathway. J. Pharm. Sci. 98 (2009), 3499–3508.
67. Zimmermann, S., Lepenies, B., Glycans as vaccine antigens and adjuvants: immunological considerations. Methods Mol. Biol. 1331 (2015), 11–26.
68. Xu, Y., et al. Designer glycopeptides for cytotoxic T cell-based elimination of carcinomas. J. Exp. Med. 199 (2004), 707–716.
69. Fujita, T., et al. Inhibitory effect of free sialic acid on complement activation and its significance in hypocomplementemic glomerulonephritis. J. Clin. Lab. Anal. 13 (1999), 173–179.
70. Egleton, R.D., et al. Improved blood-brain barrier penetration and enhanced analgesia of an opioid peptide by glycosylation. J. Pharmacol. Exp. Ther. 299 (2001), 967–972.
71. Witt, K.A., et al. Peptide drug modifications to enhance bioavailability and blood-brain barrier permeability. Peptides 22 (2001), 2329–2343.
72. Papademetriou, I.T., Porter, T., Promising approaches to circumvent the blood-brain barrier: progress, pitfalls and clinical prospects in brain cancer. Ther. Deliv. 6 (2015), 989–1016.
73. Reinhardt, A., Neundorf, I., Design and application of antimicrobial peptide conjugates. Int. J. Mol. Sci., 17, 2016, 701.
74. Shi, B., et al. Expression of asialoglycoprotein receptor 1 in human hepatocellular carcinoma. J. Histochem. Cytochem. 61 (2013), 901–909.
75. Lehr, C.-M., Gabor, F., Lectins and glycoconjugates in drug delivery and targeting. Adv. Drug Deliv. Rev. 56 (2004), 419–420.
76. McCormack, F.X., Whitsett, J.A., The pulmonary collectins, SP-A and SP-D, orchestrate innate immunity in the lung. J. Clin. Invest. 109 (2002), 707–712.
77. Brogden, N.K., Brogden, K.A., Will new generations of modified antimicrobial peptides improve their potential as pharmaceuticals?. Int. J. Antimicrob Agents 38 (2011), 217–225.
78. Roggenbuck, D., et al. Asialoglycoprotein receptor (ASGPR): a peculiar target of liver-specific autoimmunity. Auto-Immunity Highlights 3 (2012), 119–125.
79. Kramer, J.R., et al. Reinventing cell penetrating peptides using glycosylated methionine sulfonium ion sequences. ACS Cent. Sci. 1 (2015), 83–88.
80. Fox, J.L., Antimicrobial peptides stage a comeback. Nat. Biotechnol. 31 (2013), 379–382.
81. Niyonsaba, F., et al. The innate defense regulator peptides IDR-HH2, IDR-1002, and IDR-1018 modulate human neutrophil functions. J. Leukoc. Biol. 94 (2013), 159–170.
82. Scott, M.G., et al. An anti-infective peptide that selectively modulates the innate immune response. Nat. Biotechnol. 25 (2007), 465–472.
83. Powell, A.K., et al. Generating heparan sulfate saccharide libraries for glycomics applications. Nat. Protoc. 5 (2010), 821–833.
84. Mazola, Y., et al. Integrating bioinformatics tools to handle glycosylation. PLoS Comput. Biol., 7, 2011, e1002285.
85. Kumar, S., et al. GlycoCD: a repository for carbohydrate-related CD antigens. Bioinformatics 28 (2012), 2553–2555.
86. Lu, D., et al. How hydrophobicity and the glycosylation site of glycans affect protein folding and stability: a molecular dynamics simulation. J. Phys. Chem. B 116 (2012), 390–400.
87. Bohne, A., et al. W3-SWEET: carbohydrate modeling by internet. Mol. Model. Annu. 4 (1998), 33–43.
88. Cherkasov, A., et al. QSAR Modeling: where have you been? Where are you going to?. J. Med. Chem., 57, 2014, 4977.
89. Frank, M., et al. Rapid generation of a representative ensemble of N-glycan conformations. Silico Biol. 2 (2002), 427–439.
90. Zhou, Q., et al. Site-specific antibody–drug conjugation through glycoengineering. Bioconjug. Chem. 25 (2014), 510–520.
91. Rachel, N.M., Pelletier, J.N., One-pot peptide and protein conjugation: a combination of enzymatic transamidation and click chemistry. Chem. Commun. 52 (2016), 2541–2544.
92. Hossler, P., et al. Optimal and consistent protein glycosylation in mammalian cell culture. Glycobiology 19 (2009), 936–949.